ArticleJournal of cell communication and signaling2026
NRF2-CDH6-CEBPD axis suppresses ferroptosis and drives cisplatin resistance in non-small cell lung cancer.
Article in Journal of cell communication and signaling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis is a non-apoptotic form of programmed cell death driven by iron-dependent lipid peroxidation. Induction of ferroptosis has been shown to overcome chemoresistance in cancer cells. Given the importance of the nuclear factor erythroid 2-related factor 2 (NRF2) pathway in the regulation of cellular oxidative stress, this study was designed to search for NRF2-regulated genes involved in ferroptosis and chemoresistance in non-small cell lung cancer (NSCLC). Bioinformatics analysis and experimental validation indicated cadherin-6 (CDH6) as a candidate gene. The expression and role of CDH6 in NSCLC were explored. CDH6 protein partners were identified and investigated after CDH6 co-immunoprecipitation assays and mass spectrometry. Our data demonstrated that NRF2 binding to the promoter of the CDH6 gene inhibited RUNX2-mediated transcription of CDH6 in NSCLC. Clinically, CDH6 was downregulated in NSCLC tissues and correlated with more advanced tumor-node-metastasis (TNM) stage and shorter overall survival. Knockdown of CDH6 enhanced the proliferation, colony formation, tumorigenesis, and cisplatin (CDDP) resistance in NSCLC cells. Moreover, overexpression of CDH6 induced ferroptosis and increased CDDP sensitivity in CDDP-resistant NSCLC cells. Mechanistically, CDH6 associated with and sequestered CCAAT enhancer binding protein delta (CEBPD) protein in the cytoplasm and impaired the CEBPD-dependent transcription of target genes. Depletion of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.